Big pharma will feel the heat over the next 6 years as small and mid-size developers eat away at their market share and profit margins. But as far as in-house orphan drug units go, GSK has bucked the trend and rocketed up the ranking, along with the likes of Pharmacyclics who shoot up an impressive 65 places from 2013.
Comments
What’s the source of the data?
Hi Thomas,
the data came from Evaluate Pharma’s Orphan Drug Report 2013.
Here’s the link: http://www.evaluategroup.com/public/PressReleases/EvaluatePharma-New-Report-Shows-Orphan-Drug-Market-to-Reach-USD176-Billion-by-2020.aspx
Pingback: Orphan Drugs Set To Be Worth $176 Billion in 2020 - Orphan Drugs : Orphan Drugs